Drug, bio-affecting and body treating compositions inventions 02/06

20060040852 - Il-1 antagonist formulations: Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID...

20060040853 - Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras: The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis...

20060040851 - Topical compositions for the treatment, protection and restoration of skin and connective tissues: The invention relates to uses of GAG-peptide complexes and polypeptides obtained from connective tissue albeit indirectly which are substantially free of DNA for the treatment, protection and restoration of skin and connective tissues. The invention provides a topical composition comprising at least on GAG-peptide complex comprising two or three GAG-chains....

20060040850 - Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differenti: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous...

20060040854 - Prostate hyperplasia therapy: The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity....

20060040856 - Glycopegylated factor ix: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a...

20060040855 - Low efficacy gonadotropin agonists and antagonists: The present invention provides glycoprotein hormone analogs having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide. The analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond. The present invention also provides a method for stimulating fertility...

20060040857 - 1-desamino-8-a-arginyl vasopressin analogs: e

20060040858 - Novel peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also...

20060040864 - Apparatus and method for transdermal delivery of vascular endothelial growth factors: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or assembly) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In...

20060040860 - Intra-tracheal application of vascular endothelial growth factor (vegf) for the prevention of lung damages caused by hperoxia: The invention relates to the field of pulmonary diseases that are related to oxygen provision that is higher than physiological (hyperoxia) and to the use of vascular endothelial growth factor (VEGF) for treatment and prevention. Hyperoxic exposure causes a direct cellular damage in the lung and disturbs lung development. The...

20060040861 - Method of treating, preventing, and diagnosing prostate cancer: A method of treating prostate cancer in a prostate cancer patient is disclosed. In one embodiment of the present invention, the method comprises the step of decreasing or blocking the patient's leptin interaction with leptin receptor or increasing adiponectin interaction with adiponectin receptors....

20060040863 - Methods for treatment of diabetes using peptide analogues of insulin: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered...

20060040859 - Peptides, dnas, rnas, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same: Pharmaceutical compositions containing adrenomedullin antagonist peptides, DNA, RNA compounds inhibitory on adrenomedullin activity, resulting in the efficient blockade of the induction of macroangiogenesis or vasculogenesis of more than 8 μm (in case of murine models), suppress the proliferation of cancer cells due to that inhibitory effect and suppress the protective...

20060040865 - Platelet production promoting agent: The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a...

20060040862 - Xaf genes and polypeptides: methods and reagents for modulating apoptosis: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis....

20060040866 - Peptides and compounds that bind to a receptor: Peptides and compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed....

20060040867 - Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections: A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound...

20060040868 - Methods for treating premature infants: Methods of treating premature infants include administering, to an infant, an agent that increases the blood or tissue levels, production, function, or activity of hCG, LH, FSH, GnRH, or activin or that decreases the blood or tissue levels, production, function, or activity of follistatin and inhibin....

20060040870 - Enhancement of apoptosis by caspase-9 inhibitors: The present invention provides methods for inducing apoptosis in a tumor cell by contacting the cell with a caspase-9 inhibitor....

20060040869 - Pharmaceutically useful compounds: A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1-4 carbon atoms; when X is —NR4R5, R2 is...

20060040871 - Bacterial transforming agent: A method of increasing the sensitivity of a bacterial strain to a cell-wall active antimicrobial agent, to which the bacterial strain or a progenitor strain from which the bacterial strain has evolved is sensitive is described. The method comprises the step of exposing said bacterial strain to a transforming agent...

20060040872 - Calcium channel inhibitor: The present invention relates to an agent which inhibits or suppresses calcium channel where dipeptide Val-Tyr (VY) or a substance containing the same is an effective ingredient. Examples of the substance containing VY are hydrolysate (sardine peptide) of fish meat of sardine, etc., and VY or VY-containing substance is also...

20060040873 - Composition for use in prophylaxis and or treatment: The present invention relates generally to a composition for use in the prophylaxis and/or treatment of pain. More particularly, the present invention relates to a composition for use in the prophylaxis and/or treatment of chronic neuromuscular pain. The composition of the present invention is particularly useful in the prophylaxis and/or...

20060040874 - Process for the preparation of topiramate: The present invention relates to a process for the preparation of topiramate, intermediates in this process and a process for the preparation of these intermediates....

20060040875 - Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b): A UGT2B inhibitor capable of increasing the bio-availability of a drug, being a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol,...

20060040876 - Modulation of peroxisome proliferator-activated receptors: A method of treating a peroxisome proliferators-activated receptors related disease by administering to a subject in need thereof an effective amount of a modulator of 15-keto prostaglandin-Δ13-reductase. Also disclosed are methods of identifying a compound for inhibiting activity of the reductase and of lowering blood glucose levels by administering to...

20060040877 - Novel spinosyn-producing polyketide synthases: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns....

20060040884 - Antisense oligonucleotides directed to genes regulated by trapoxin-induced hdac inhibition: Antisense compounds, compositions and methods are provided for modulating the expression of trapoxin A regulated genes, including but not limited to those genes induced by ectopic expression of p21waf1 that are disclosed herein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding these genes. Methods of...

20060040878 - Bacterial antigen induced bone morphogenesis: Bone growth following a spinal fusion procedure is enhanced by packing the fusion site with a mixture of a bone material such as allograft or autograft, and an antigen produced from bacteria or parasitic organisms. A composition for inducing bone morphogenesis also is disclosed....

20060040885 - Bioprosthetic heart valves: The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration,...

20060040879 - Chloroquine coupled nucleic acids and methods for their synthesis: This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount...

20060040886 - Compositions and methods for treatment of prostate and other cancers: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for...

20060040882 - Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells: Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference...

20060040880 - Methods and compositions for treating neuropathic pain: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention...

20060040883 - Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna: This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such...

20060040881 - Modulators of coagulation factors: The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass....

20060040887 - Method for stimulating the immune, inflammatory or neuroprotective response: Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective...

20060040889 - 2-polycyclic propynyl adenosine analogs having a2a agonist activity: c

20060040888 - 2-propynyl adenosine analogs with modifed 5'-ribose groups having a2a agonist activity:

20060040890 - Anti-viral nucleosides: 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process....

20060040895 - Aesthetic use of hyaluronan: A method to rejuvenate tissue by injection of a solution containing between about 0.5% and about 10% hyaluronic acid is described. The application of the solution to tissue regions having wrinkles, line, creases, abnormalities and the like is effective in diminishing the signs of aging....

20060040894 - Compositions and methods using hyaluronic acid: Compositions and devices including hyaluronic acid and a compound that inhibits degradation of hyaluronic acid, and methods of making and using same....

20060040893 - Immunomodulatory methods using oligosaccharides: Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper...

20060040891 - Lipid a and other carbohydrate ligand analogs: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of...

20060040892 - Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles: A method for synthesizing uniformly sized hyaluronic acid (“HA”) particles that are substantially free from oil and surfactant contaminants. The method comprises crosslinking HA chains with 1-ethyl-3-(3-dimethlyaminopropyl) carbodiimide hydrochloride (“EDAC”) and adipic acid dihydrazide in a water/acetone mixture....

20060040896 - Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity: A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously,...

20060040897 - Compositions for treating and/or preventing diseases characterized by the presence of metal ions: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some...

20060040898 - Novel boronate esters: The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin....

20060040899 - Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies: e

20060040900 - R(-)-11-hydroxyaporphine derivatives and uses thereof: The invention features derivatives of R(—)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith....

20060040901 - Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants: The present invention discloses new cyclic glycerophosphates and cyclic popandiol phosphates and pharmaceutical compositions comprising said compounds for promoting neural activity such as neuronal outgrowth, nerve growth, prevention of nerve degeneration and nerve rescue....

20060040902 - Compunds useful as pesticides: Compounds useful to control pests are provided....

20060040903 - Methods of use related to xerostomia: The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and...

20060040904 - Vaginal cream compositions, kits thereof and methods of using thereof: The present invention is directed to pharmaceutical vaginal cream compositions comprising a conjugated estrogen and a stabilizer. The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated...

20060040905 - Formulation of nefopam and its use in the treatment of pain: (+)-Nefopam is formulated for intranasal administration, for use in the treatment of pain....

20060040910 - Macrocycles useful in the treatment of alzheimer's disease: for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods...

20060040911 - Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus): A method for treating and/or preventing the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered thereto an effective amount of bioflavonoids extract derived from fructus crataegus such as; rutin, quercetin, kaempferol and vitexin or a mixture thereof....

20060040908 - Novel chalcogenoxanthylium dyes for purging blood pathogens and for photodynamic therapy: Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds....

20060040906 - Piperazine urea derivatives as melanocortin-4 receptor agonists: Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes....

20060040909 - Selenophene compounds: In formula (I), each of R1 and R2, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, heteroaryl, or C(O)Ra; X is Se, S, O, or NRb; and each of R3, R4, R5, and R6, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; in which...

20060040907 - Triptolide analogs for the treatment of autoimmune and inflammatory disorders: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds....

20060040912 - Compounds for pdt: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or...

20060040914 - Meso-substituted porphyrins: Meso-substituted porphyrins of general formula (I) suitable for the use as photosensitising agents, in particular in photodynamnic therapy, are herein described....

20060040913 - Porphyrins and related compounds: New porphyrins and chlorins including bacteriochlorins, for photodynamic therapy....

20060040915 - Process for the preparation of cefdinir: The present invention relates to a process for the preparation of cefdinir on an industrial scale....

20060040916 - Carbapenem compound crystals and injection preparations: The present invention provides carbapenem hydrochloride trihydrate crystals, which are chemically stable, easily purified and useful as antimicrobial agents, a process for producing them, and a powdery charged preparation for injection containing them. That is, it provides carbapenem hydrochloride trihydrate crystals having a powdery X-ray diffraction pattern containing lattice distances...

20060040917 - Benzoxazepine derivatives as selective estrogen receptor modulators: The present invention is directed to novel benzoxazepine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor....

20060040918 - Benzo d!azepine derivatives for the treatment of neurological disorders: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders....

20060040919 - Bronchorelaxing compounds: wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl,...

20060040922 - Aripiprazole, olanzapine and haloperidol pamoate salts: The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio...

20060040920 - Crystal forms of olanzapine and processes for their preparation: The invention relates to a process for the preparation of form I of olanzapine, crystallized from a solvent mixture which comprises 2-propanol, some pseudopolymorphic forms, namely solvates of olanzapine, anew polymorphic form A of olanzapine, and processes for the preparation thereof....

20060040921 - Process and intermediates for the preparation of olanzapine: The invention provides an improved process for preparing Olanzapine as well as intermediates therefor....

20060040923 - Benzodiazepine derivatives and pharmaceutical compositions containing them: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; —each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio,...

20060040924 - Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic: The present invention refers to the use of derivatives of aryl (or heteroaryl) azolylcarbinols of general formula (I), and their physiologically acceptable salts, as medicinal products for human and/or animal therapeutics for the treatment of renal colic....

20060040925 - Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity: Cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man....

20060040926 - Fluorescent fused-ring triazoles that inhibit cell proliferation and uses thereof: Fused-ring triazole compounds which inhibit proliferation of cells and exhibit a unique and intense fluorescence are provided. Also provided are methods for synthesizing these compounds and methods for using these compounds to inhibit cell proliferation and infection and to label and fluorescently detect selected molecules....

20060040927 - Heterocyclic antiviral compounds: Compounds having the formula I wherein A, m and R1 are herein defined are Hepatitis C virus polymerase inhibitors. Also disclosed are compositions and methods for treating diseases mediated by HCV and for inhibiting hepatitis replication. Also disclosed are processes for making the compounds and synthetic intermediates used in the...

20060040928 - Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds: m

20060040929 - (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1h)-thione and method of preparation thereof:

20060040930 - Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same:

20060040931 - Benzomorpholine derivatives:

20060040933 - Nonsteroidal antiinflammatory agents: are useful in the treatment of inflammation....

20060040932 - Stable crystalline form of bifeprunox mesylate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethanesulfonate): The invention relates to a stable polymorphic form of the compound 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate (INNM bifeprunox mesylate), a method for the preparation of said polymorphic form and its use in pharmaceutical products, especially in pharmaceutical products for the treatment of psychotic disorders and Parkinson's disease....

20060040934 - Use of stat-6 inhibitors as therapeutic agents: The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments....

20060040935 - Method of treating impotence due to spinal cord injury: A class of cGMP PDE inhibitors, including sidenafil and pharmaceutically acceptable salts thereof, which can be used to treat sexual dysfunction in male and female animals, especially humans, with a spinal cord injury. The invention can be used to treat sexual dysfunction in male animals that exhibit essentially no residual...

20060040936 - Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors: c

20060040937 - N-aroyl cyclic amines as orexin receptor antagonists: This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals....

20060040938 - Substituted fullerene compositions and their use as antioxidants: i

20060040939 - Benzamide inhibitors of the p2x, receptor:

20060040943 - 3-furanyl analogs of toxoflavine as kinase inhibitors: the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R1 represents C1-4alkyl, C1-4alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C1-4alkyloxycarbonyl; R2 represents hydrogen or...

20060040944 - 5-aza-7-deazapurine derivatives for treating flaviviridae: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and...

20060040942 - 5-ethylimidarotriazones: The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases....

20060040941 - 7-aminoimidazotriazones: The invention relates to novel 7-amino-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases....

20060040940 - Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands: The present invention provides a pharmaceutical composition providing a compound of formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable excipient: (I), in which: X and Y independently represent CH or N, with the proviso that if X is CH then Y is also CH; R1 represents...

20060040945 - Annellated pyrrole compounds as proton pump inhibitors for treating ulcer: Inhibiting gastric proton pump in a mammal is accomplished by the use of a compound of formula (1) wherein the variables have the meaning given in the present description. A preferred compound of formula (2) is this treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or lesions...

20060040946 - Methods and compositions for the treatment of metabolic disorders: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated....

20060040947 - Amino-heterocycles as vr-1 antagonists for treating pain: the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than two, of W, X and Y...

20060040948 - Macrocyclic beta-secretase inhibitors: R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering...

20060040949 - Novel compounds with antibacterial activity: The present invention describes novel anti-bacterial compounds of formula (I)....

20060040950 - Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists: This invention concerns substituted I-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of schizophrenia, anxiety, depression, emesis and IBS. The...

20060040951 - Use of 5-ht2 receptor antagonists for the treatment of sleep disorders: The invention relates to the use of 5-HT2 receptor antagonists for the preparation of a medicament for extending both non-REM sleep an REM sleep....

20060040953 - Diketopiperazine salts for drug delivery and related methods: Biologically active agent delivery compositions, which comprise diketopiperazine carboxylate salts are provided. Related methods for making and using the biologically active agent delivery compositions are also provided....

20060040952 - Il-8 receptor antagonists: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20060040954 - Soluble amide & ester pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers....

20060040955 - 4-pyrimidineamine compounds and their uses as anti-proliferative agents: The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers....

20060040956 - Substituted alkylamine derivatives and methods of use: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject...

20060040957 - Bicyclic pyrimidine matrix metalloproteinase inhibitors: l

20060040958 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060040959 - Adenosine a3 receptor modulators: wherein R, R2, R3 and A have the meanings given in the specification, are endowed with selective A3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A3 receptor, or can be used in a diagnostic application...

20060040961 - Furanopyrimidines: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial...

20060040960 - Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders: This invention relates to a compound of Formula (I) wherein Y is CH or N; Ar1 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each selected independently from (C1-C3)alkoxy halo, OH, CF3, CN, NO2 and (C1-C3)alkyl, said alkyl being optionally substituted with CF3; Ar2 is phenyl...

20060040962 - Pharmaceutical formulations: Disclosed are pharmaceutically acceptable PDE V inhibitor Formulations that are especially useful for treating male erectile and female sexual dysfunction and other physiological disorders....

20060040963 - Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to...

20060040964 - Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines: Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric...

20060040965 - Pyrrolo[2,3-d]pyrimidines that modulate ack1 activity: b

20060040966 - Substituted aryl-amine derivatives and methods of use: wherein R, R1 and R2 for each formula are defined herein. The invention further includes analogs, prodrugs and pharmaceutically acceptable salts and derivatives of Formulas I and II, as well as pharmaceutical compositions, medicaments and methods thereof for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer...

20060040967 - Pyrimidine derivative as selelctive cox-2 inhibitors: e

20060040968 - 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:...

20060040969 - Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular...

20060040970 - Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group: (wherein R1 is methyl, cyclopropylmethyl or the like; R2 and R3 are hydroxy, methoxy, acetoxy or the like; both Y and Z are valence bonds, —C(═O)— or the like; X is C2-C5 carbon chain (one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen) constituting a part...

20060040971 - Rapamycin polymorphs and uses thereof: The present invention provides rapamycin polymorph Form II. This invention also provides processes for preparing rapamycin polymorph Form II and pharmaceutical compositions including rapamycin polymorph Form II....

20060040972 - Pyrazolonaphthyridine derivative: wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and...

20060040973 - Novel guanidine mimics as factor xa inhibitors: e

20060040974 - Retroviral protease inhibitors: HIV protease inhibitors are disclosed which are characterized as having both hydroxyethylamine and N-heterocyclic moieties....

20060040975 - Fused ring nk1 antagonists: V

20060040976 - Thiobenzimidazole derivatives:

20060040979 - 3-aryl-2-hydroxypropionic acid derivative i: A novel 3-aryl-2-hydroxypropionic acid derivative, a process and intermediate for its manufacture, pharmaceutical preparations containing it and the use of the compound in clinical conditions associated with insulin resistance....

20060040978 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is...

20060040977 - 5-ht7 receptor ligands: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline propyl sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is...

20060040980 - Ionophores as cancer chemotherapeutic agents: This invention relates to anti-cancer uses of ionophores of which clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) is a prototype drug. The present invention is further directed toward using ionophores such as clioquinol alone, or in combination with metals (e.g., zinc or copper, manganese) as anti-cancer and anti-angiogenic agents. This invention further relates to the...

20060040981 - Use of phosphodiesterase-4 inhibitors as enhancers of cognition: The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a...

20060040982 - 2-substituted quinoline compounds and their uses: The present disclosure provides 2-substituted-quinoline compounds that inhibit the IgE receptor signaling cascade that leads to the release of chemical mediators, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and/or prevention of...

20060040983 - Quinolinyl-pyrrolopyrazoles: A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound....

20060040984 - Novel piperidine derivatives for use in the treatment of chemokine medicated disease states: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state....

20060040985 - Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient: wherein A is a group represented by L-W [wherein L is a bond or CH2; and W is O, SOn (wherein n is 0 to 2), or —NR7— (wherein R7 is hydrogen or lower alkyl)]; each of G1 and G2 is (CH2)r (wherein r is 0 to 2), provided that...

20060040986 - Erythropoietin production accelerator: R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof....

20060040987 - Ultrashort-acting opioids for transdermal application: The subject invention concerns novel analogs of fentanyl opioids. The subject invention also concerns methods for synthesizing the compounds of the invention. The invention also concerns methods for treating pain in a patient by administering a compound of the invention to a person in need of such treatment....

20060040988 - Cox-2 inhibiting pyridine derivatives: e

20060040989 - N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion:

20060040990 - Epothilone derivatives, process for their production, and their pharmaceutical use:

20060040991 - Pharmaceutical presentation form for oral administration of a poorly soluble active compound, process for its preparation and kit: The invention relates to a pharmaceutical presentation form for the oral administration of indibulin in the form of an aqueous drink solution, and a method for its preparation....

20060040993 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt: Disclosed are 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salts, or solvates thereof; processes for preparing such compounds, compositions comprising such compounds and the use of such compounds in medicine....

20060040992 - Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines: There are provided novel compounds of formula (I) wherein T, X, Y and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric...

20060040994 - Substituted amide beta secretase inhibitors: R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering...

20060040995 - Method for preparing hydroxypicolinic scid derivatives: The invention concerns a method for preparing compounds of general formula (I) wherein: n, Q1, Q2, X1, X2, Y and Z are as defined in the description....

20060040996 - Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer...

20060040997 - Benzthiazole-3 oxides useful for the treatment of proliferative disorders: e

20060040998 - Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof:

20060040999 - Cetp inhibitors: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring...

20060041000 - 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase: 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and analogues useful as inhibitors of macrophage elastase are disclosed....

20060041001 - Novel imidazolic compounds, method for preparing same and use thereif as medicines: wherein R1 is hydrogen, fluoro or methoxyl, R1 being in position 2, 3, 4 or 5 of the aromatic carbocycle; R2 is hydrogen or methyl; R3 is hydrogen, methyl or ethyl; and their pharmaceutically acceptable acid addition salts, hydrates of their pharmaceutically acceptable acid addition salts as well as the...

20060041002 - Guanylhydrazone compounds, compositions, methods of making and using: e

20060041003 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone...

20060041004 - Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4h-carbazol-4-one and ondansetron therefrom: The present invention provides a rapid, high-yielding process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one without using a secondary amine as a catalyst, and without using glacial acetic acid as a solvent. The present invention further provides a rapid, high-yielding process for preparing ondansetron from 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one without using alumina as a catalyst....

20060041005 - Process for the synthesis c-2, c-3 substituted n-alkylated indoles useful as cpla2 inhibitors: e

20060041006 - Pde4b inhibitors and uses therefor: Compounds active on phosphodiesterase PDE4B are provided. Also provided herewith are compositions useful for treatment of PDE4B-mediated diseases or conditions, and methods for the use thereof....

20060041007 - Metastable benzoxepne derivatives which can be used in the treatment of dyslipidaemia a therosclerosis and diabetes, pharmaceutical compositions comprising them and processes for the preparation thereof: The present invention relates to novel metastable derivatives of benzoxepines of the formula (I) in which n represents 0, 1 or 2; and the radicals R, which may be identical or different, are alkyl or alkoxy groups, or halogen atoms, which can be used in the treatment of dyslipidaemia, atherosclerosis...

20060041008 - Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders: The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders....

20060041009 - Pharmaceutical compound containing silymarin and carbopol, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus: The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (β cells). It therefore regulates the serum levels of...

20060041010 - (-)-epigallocatechin gallate derivatives for inhibiting proteasome: (−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R1 is selected from the group of —H and C1 to C6 acyl group; R2, R3, and...

20060041011 - Prodrugs of propofol, compositions and uses thereof: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting....

20060041012 - Cis-diiodo-(trans-l-1,2-cyclohexanediamine) platinum (ii) complex and processes for preparing high purity oxaliplatin: The present invention is related to pure cis-diiodo-(trans-L-1,2-cyclohexanediamine) Pt (II) complex, and a process of its preparation. The present invention is further related to the preparation of oxaliplatin using said cis-diiodo-(trans-L-1,2-cyclohexanediamine) Pt (II) complex....

20060041013 - Alanosine formulations and methods of use: Stable liquid formulations of the anti-tumor agent L-alanosine are described. These formulations preferably comprise L-alanosine in an aqueous environment having a basic pH, preferably in the range of about pH 8-9. The alanosine formulations and compositions disclosed herein can be used for various purposes, including the treatment of various cancers,...

20060041014 - Treatment of male sexual dysfunction: The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED....

20060041015 - Use of treosulfan and derivaties thereof for treating multiple sclerosis: The invention relates to the use of treosulfan and/or derivatives thereof for producing a pharmaceutical composition used in the treatment of multiple sclerosis....

20060041016 - Composition and method for the treatment of psoriasis: The use of a prostaglandin A2 derivative, and prodrugs of the compound, for the manufacture of a medicament for the treatment and/or alleviation of psoriasis is presented, as well as a method of treatment, involving the topical application of such prostaglandins. Compositions containing a therapeutically active, and physiologically acceptable amount...

20060041018 - Method of monitoring/controlling thysanoptera: e

20060041017 - Synergistic conjugated linoleic acid (cla) and carnitine combination: The present invention relates to the unexpected discovery that a combination of effective amounts of carnitine (in any form, as described in further detail herein) and conjugated linoleic acid (CLA) administered to a patient in need thereof exhibits synergistic activity in treating obesity by reducing fat mass and overall weight...

20060041019 - Inhibitor of anticancer drug side effect: An object of the present invention is to provide a novel agent for suppressing side effects of an antitumor agent, which can suppress side effects caused by the use of an antitumor agent, such as hair loss. The present invention provides an agent for suppressing side effects of an antitumor...

20060041020 - Novel cyclohexyl sulphones:

20060041021 - Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists: Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health,...

20060041022 - Treatment of amyotrophic lateral sclerosis with nimesulide: The present invention relates to methods for delaying the onset or progression of motor impairment associated with amyotrophic lateral sclerosis in a subject by administering to the subject a therapeutically effective amount of nimesulide. It further provides for a means of detecting and monitoring the progression of amyotrophic lateral sclerosis...

20060041023 - Facially amphilic polymers and oligomers and uses thereof: The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions....

20060041024 - Polycationic compounds and uses thereof: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally,...

20060041025 - Diphenyl ether antimicrobial compounds: wherein A1, A3, A6, and A8 independently represent CH or N; A2 represents N or C—X1a—R1; A4 represents N or C—X2b—R2; R1 and R2 independently represent H, or a hydrocarbon containing a minimum of one carbon atom and a maximum of twenty six carbon atoms, wherein the hydrocarbon is unsubstituted,...

20060035809 - Apoptosis-mimicking natural vesicles and use thereof in medical treatment: Natural biological vesicles with membranes which have lost phospholipid symmetry, especially those presenting phosphatidyl serine on outer membrane surfaces, such as red cell ghosts, are administered to mammalian patients, in immune system modifying amounts, for treatment or prophylaxis of inflammatory cytokine-related disorders, including autoimmune disorders, neurodegenerative disorders and endothelial dysfunction...

20060035810 - Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto: Provided is a method of increasing 3,4,5,6-tetrakisphosphate by increasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase, and a method of decreasing 3,4,5,6-tetrakisphosphate by decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase. A method of reducing salt, fluid or mucous secretion in a subject, comprising increasing the activity of inositol 1,3,4,5,6...

20060035811 - Methods of treating dry eye disease with lantibiotics: The treatment of dry eye disease with lantibiotics such as duramycin is described, along with pharmaceutical formulations useful for carrying out such treatments....

20060035812 - Neuroprotective dietary supplement: The invention relates to a novel dietary supplement mixture having improved neuroprotective activity and preventing, ameliorating or counteracting neurodegeneration and preventing, counteracting and/or improving cognitive function decline. It also provides a dietary supplement, which is to be administered in an oral dosage form....

20060035813 - Methods and formulations comprising agonists and antagonists of nuclear hormone receptors: Novel compounds, pharmaceutical compositions, and methods are provided for modulating processes mediated by nuclear hormone receptors. A partial or complete agonist or antagonist modulates, directly or indirectly, an activity of one or more nuclear hormone receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs),...

20060035815 - Pharmaceutical compositions for delivery of ribonucleic acid to a cell: What is disclosed is a pharmaceutical composition for administration of a double stranded ribonucleic acid (dsRNA) molecule to an animal, comprising the dsRNA molecule and a peptide, wherein the dsRNA molecule comprises about 10 to about 40 base pairs, wherein the peptide comprises about 5 to about 40 amino acids...

20060035814 - Reagents and methods for smooth muscle therapies: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration....

20060035816 - Method and composition for inhibiting or slowing blood coagulation: A method and composition for inhibiting or slowing blood coagulation includes lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin....

20060035818 - Use of corticotroph-derived glycoprotein hormone to induce lipolysis: The use of corticotroph-derived glycoprotein hormone (CGH) to induce lipolysis, treat obesity, insulin resistance, and type II diabetes is described....

20060035817 - Use of galectin-3 and galectin-7 to promote the re-epithelialization of wounds: Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3...

20060035820 - New derivatives of echinocandine, their preparation process and their use as antifungals: t

20060035819 - Novel molecule: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the...

20060035821 - Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases: Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions....

20060035822 - Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases: Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions....

20060035825 - Alpha 5 beta 1 and its ability to regulate the cell survival pathway: The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma,...

20060035830 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliamy, urethral, esophageal, and tracheal/bronchial obstructions....

20060035831 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060035832 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060035833 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060035829 - Chemokine combinations to mobilize progenitor/stem cells: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 in combination with the CXCR2 chemokine GROβ, including its modified forms, are disclosed....

20060035834 - Compositions and methods for diagnosing and treating an inflammation: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in...

20060035827 - Compositions and methods for the treatment or prevention of gallbladder disease: Compositions and methods for the treatment or prevention of gallbladder disease are provided. In particular, pharmaceutical compositions containing an amount of serine proteinase inhibitor such as potato proteinase inhibitor II effective to induce gallbladder contraction in a host are provided. The compositions can be administered to individuals having a body...

20060035828 - Direct activation of atiii in whole blood and plasma and uses thereof: Methods of activating ATIII in situ in a blood product are disclosed, as is the use of such methods and blood products in treating infectious diseases, inflammatory disorders and diseases or conditions that are mediated by thrombin activation....

20060035823 - Isolated fragments of p62 nucleoporin and uses thereof: The invention is directed to isolated protein fragments of p62 nucleoporin including deletion isoforms and nucleic acid sequences encoding these deletion isoforms. The isolated deletion isoforms disclosed herein include the sequences: SEQ. ID NO.:1 MSGFNFGGTG APTGGFTFGT AKTATTTPAT GFSFSTSGTG GFNFGAPFQP ATSTPSTGLF SLATQTPATQ TTGFTFGTAT LASGGTGFSL GIGASKLNLS NTAATPAMAN PSGFGLGSSN LTNAISSTVT SSQGTAPTGF VFGPSTTSVA PATTSGGFSF...

20060035835 - Novel protein, production and use thereof: The present invention relates to a novel SSD (sterol-sensing domain)-containing protein derived from human liver, human testis and human brain, or a salt thereof, and a DNA encoding the same. Studies on the tissue-specificity of the protein expression, the expression change depending the intracellular cholesterol level, production of the transformant,...

20060035826 - Promotion of axonal regeneration: The present invention concerns a method of promoting axonal regeneration. In particular, the invention concerns a method of promoting the growth or regeneration of neurons, and treating disease or conditions associated with the loss, loss of function or dysfunction of nerve cells, in particular thalamic nerve cells, by administering a...

20060035836 - Treatment of acute coronary syndrome with an exendin: The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as...

20060035824 - Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation: The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass...

20060035837 - Compounds that inhibit hsp90 protein-protein interactions with iap proteins: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds....

20060035838 - Drug therapy for celiac sprue: A ministering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten....

20060035839 - Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments: The invention relates to a multimeric molecule which can imitate a natural multimeric proteinaceous ligand. The invention also relates to a multimeric molecule as defined above which is characterised in that it has the following general formula: A-Xn, wherein: n is equal to 3, 4, 5 or 6; A denotes...

20060035841 - D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture: e

20060035840 - Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof: wherein X1 represents Nor CR1; X2 represents Nor CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a...

20060035842 - Ophthalmic composition: It is an object of the present invention to provide an ophthalmic composition, wherein: the ophthalmic composition assures a sufficiently high degree of safety to eyes of the lens wearer; the ophthalmic composition reduces symptoms such as an unpleasant feeling or dryness of the eyes; the ophthalmic composition does not...

20060035843 - Tanaproget derivatives, metabolites,and uses thereof: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided....

20060035844 - Preventive or remedy for diseases caused by hyperglycemia: The present invention provides pharmaceutical compositions comprising as an active ingredient a selective SGLT1 inhibitor (e.g., an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect), which have a wider range of inhibitory effect on carbohydrate absorption and a hypoglycemic effect caused by fructose ingestion at regular diets and...

20060035845 - Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract: wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, T represents an anti-inflammatory subunit that can be a steroid or nonsteroid (nonsteroidal moiety) derived from a non-steroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID) and L represents a linker covalently linking M and T....

20060035847 - Glucopyranosyloxyprazole derivatives and use thereof in medicines: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo (lower alkyl) group or a halogen...

20060035846 - Preventing/correcting functional disorders of the pilosebaceous unit of mammals: Orally administratable cosmetic compositions, notably formulated as food supplements, useful for the prevention and/or treatment of functional disorders of the pilosebaceous structural unit of mammals, in particular by combating the cutaneous activation of the androgens over time, and especially for the treatment of oily and/or hyper-seborrheic skin and/or scalp, thin...

20060035848 - Broad-spectrum inhibitor of viruses in the flaviviridae family: The present invention relates generally to the fields of chemistry and molecular biology. More particularly, it concerns the use of compounds to treat viral infection. In a preferred embodiment, 2-amino-8-(β-D-ribofuranosyl) imidazo [1,2-a]-s-triazine-4-one may be used to treat infection by viruses of the Flaviviridae family....

20060035854 - Compositions and methods for coating medical devices: The present invention provides compositions and methods for coating medical devices with pharmaceutical agents and devices coated with the compositions. The coated devices provide controlled or sustained release of pharmaceutical agents for the treatment of wounds or disease....

20060035852 - Genetic products differentially expressed in tumors and the use thereof: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. Said invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which...

20060035849 - Methods and composition for modulating type i muscle formation using pgc-1 alpha: The invention provides novel methods and compositions for modulating type I muscle formation through modulation of PGC-1α activity or expression. Also provided are methods for identifying compounds that modulate type I muscle formation through modulation of PGC-1α activity or expression. Further provided are methods for treating disorders associated with type...

20060035857 - Methods and compositions for the diagnosis and treatment of cancer: Methods for the treatment of squamous cell carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities....

20060035858 - Methods for modulating lipoprotein and cholesterol levels in humans: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided....

20060035853 - Methods for tailoring the immune response to an antigen or immunogen: The invention relates to methods and reagents for immunizing animals to elicit specific cellular and humoral immune-responses against specific antigens, such as viral antigens, including HBsAg antigen. The invention provides methods of using specifically prepared immunogen in fresh or lyophilized liposome, proper routes of administration of the immunogen, proper doses...

20060035850 - Plant thymidine kinases and their use: This invention relates to novel plant thymidine kinases and their use in gene therapy. More specifically the invention provides novel thymidine kinases derived from tomato, pine, rice or thale cress. In further aspects the invention provides novel polynucleotides encoding the plant thymidine kinases, vector constructs comprising the polynucleotide, host cells...

20060035855 - Purified polypeptides having il-13 receptor activity: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4....

20060035856 - Purified polypeptides having il-13 receptor activity: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor α and/or IL13 receptor β and uses thereof....

20060035859 - Treating severe and acute viral infections: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase...

20060035851 - Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair: It is described a composition comprising an effective amount of the HMGBl protein or functional parts thereof, of HMGBl expressing vectors, for the treatment of tissue damage and/or to promote tissue repair and regeneration. It is further described a composition comprising an effective amount of an antagonist of the HMGBl...

20060035860 - Resin composition with biodegradable non-liquid-crystalline and liquid-crystalline polymers: Processes for producing and recycling resin composition, which comprises a biodegradable polymer and a biodegradable liquid crystalline polymer, are provided. Also, a process for recycling waste paper is disclosed....

20060035861 - Compositions of polyacids and polyethers and methods for their use as dermal fillers: The present invention relates to improved methods for filling the skin for cosmetic or medical purposes. Compositions comprising carboxymethyl cellulose (CMC), polyethylene oxide (PEO) and calcium ions can be made and have physical properties that depend on the amounts and types of CMC, PEO, and calcium ions to form ioniclaly...

20060035862 - Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration: The invention relates to new formulations for improving the local tolerance of intravenously administered 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof....

20060035864 - Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders: The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension....

20060035863 - Noncardiotoxic pharmaceutical compounds: The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de...

20060035865 - Lipid-rich plaque regressing agents: in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is —NR1— (in which R1 is a hydrocarbon or the like); D is a C1-3 alkylene group or the like; E is —NH— or the...

20060035867 - Methods of treating cancer and the pain associated therewith using endothelin antagonists: The instant invention is directed to methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist....

20060035866 - Phosphonate compounds having immuno-modulatory activity: The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20060035868 - Functionalized stilbene derivatives as improved vascular targeting agents: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms...

20060035869 - Inhibitors of epoxide hydrolases for the treatment of hypertension: wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is...

20060035870 - Carboxylic acid derivatives as ip antagonists: R4is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and...

20060035872 - Process for the preparation of 3-oximino steroids: The present invention provides a method of preparing norelgestromin or norgestimate by reacting the corresponding 3-oxosteroid precursor with hydroxylamine HCl and a base to obtain a reaction mixture forming norelgestromin or norgestimate; monitoring the anti/syn ratio of the norelgestromin or norgestimate produced in the reaction mixture; adding a base to...

20060035871 - Pulverulent phytosterol formulations: A pulverulent phytosterol formulation comprising at least one phytosterol having a mean particle size ranging from 0.01 to 100 μm, a process for producing the pulverulent phytosterol formulation, and a food supplement, an animal feed, food or pharmaceutical or cosmetic preparation comprising the phytosterol formulation....

20060035876 - Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory bone or joint disease: The present invention relates to pharmaceutical compositions and methods of using such compositions for the treatment of inflammatory diseases of the bone and joints. The compositions comprise a catalyst for the dismutation of superoxide, which is a non-proteinaceous mimetic of superoxide dismutase, in combination with a corticosteroid. The combination is...

20060035877 - Method and compositions for treating pulmonary diseases: This invention relates to treating pulmonary diseases such as chronic obstructive pulmonary disease or asthma by administering a phosphodiesterase 4 inhibitor in combination with anti-inflammatory corticosteriod....

20060035873 - Methods for inducing apolipoprotein e secretion: The invention provides a method for increasing apolipoprotein E (ApoE) in plasma and in tissues of a mammal by using a combination of an ApoE increasing amount of an activator of the orphan nuclear receptor FXR and an ApoE increasing amount of an activator of the orphan nuclear receptor LXRα....

20060035874 - Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids: This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions comprising specific anticholinergic agents, β-2 agonists and corticosteroids....

20060035875 - Remedy for hormone-dependent cancer: A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase...

20060035878 - Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor: The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have...

20060035879 - Organic compounds: A drug delivery device or system comprising: a) a medical device, e.g. a coated stent or stent-graft, adapted for local application or administration in hollow tubes; and in conjunction therewith, b) a therapeutic dosage of an anti-inflammatory ascomycin derivative, such as pimecrolimus, e.g. affixed to the medical device, and use...

20060035880 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases: The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed....

20060035881 - Use of targeted oxidative therapeutic formulation in endodontic treatment: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an...

20060035882 - Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (vr1) activity: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical...

20060035883 - Novel serotonin receptor ligands and their uses thereof: wherein X is —CH or —N—. Y is selected from the group consisting of —CR10R11, —NR12, —O—, —S—, —SO—, and —SO2—. R1 to R12 are various substituents selected to optimize the physicochemical and biological properties such as receptor binding, receptor selectivity, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds...

20060035884 - N-cyclic sulfonamido inhibitors of gamma secretase: e

20060035885 - 8-substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal...

20060035886 - Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors: e

20060035888 - Memantine as adjunctive treatment to atypical antipsychotic in schizophrenia patients: The present invention provides a method for treating schizophrenia in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of memantine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount an atypical antipsychotic. The method of the present invention embodies both...

20060035887 - Process for preparing olanzapine: A process for preparing olanzapine comprising methylation of N-demethyl olanzapine with a methylating agent in a solvent comprising dichloromethane, methanol, or a mixture thereof....

20060035889 - Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists: Methods for screening specific biological endpoints that can be utilized to identify potential therapeutic agents for METH addiction. In one aspect of the invention, the methods involve reversal of behavioral sensitization and/or conditioned place preference in an animal previously treated with METH in the presence of a known amount of...

20060035890 - Compounds and methods for the treatment of ubiquitin conjugating disorders: The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders....

20060035891 - Cycloalkyl substituted pyrimidinediamine compounds and their uses: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers....

20060035892 - Nitrosated imidazopyridines: The invention relates to nitrosated imidazopyridines of a certain formula (I), in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion-inhibiting, anti-inflammatory and antibacterial properties....

20060035893 - Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders: The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the...

20060035895 - Isoxazoline derivatives useful as antimicrobials: e

20060035894 - Morpholine derivatives: wherein A is S or O; R is H; Ar is an optionally substituted phenyl group; X is an optionally substituted phenyl group, a C1-C4 alkyl, a C3-C6 cycloalkyl group or a CH2(C3-C6 cycloalkyl) group; R′ is H or C1-C4 alkyl; and each R1 is independently H or C1-C4 alkyl;...

20060035896 - Lpaat-beta inhibitors and uses thereof: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPMT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity....

20060035897 - Trifluoromethyl substituted benzamides as kinase inhibitors: pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases, especially of ephrin receptor kinases, and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the...

20060035898 - Fused ring heterocycle kinase modulators: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity....

20060035899 - Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric g protein: The invention relates to the use of cysteine derivatives for preparing a medicament intended to treat diseases which result from the formation of the heterotrimeric G protein. These diseases include in particular diseases linked to the following biological functions or disorders: smell, taste, perception of the light, neurotransmission, neurodegeneration, endocrine...

20060035900 - Crystalline forms of ( 6r)-l-erythro-tetrahydrobiopterin dihydrochloride: Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations....

20060035904 - Antineoplastic combinations: This invention provides the use of a combination of an mTOR inhibitor and an antimetabolite antineoplastic agent in the treatment of neoplasms....

20060035902 - Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament: Disclosed are hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, processes for preparing them and their use as pharmaceutical compositions....

20060035901 - Methotrexate derivatives useful for treating cancer and arthritis: The present invention provides novel derivatives of MTX. The novel derivatives have increased selectivity, inhibit the activity of Her2, EGFR, or B-Raf to a greater degree than MTX, and display greater antiproliferative activity than MTX. Also provided are pharmaceutical compositions containing the novel derivatives, to methods of preparation of such...

20060035903 - Storage stable perfusion solution for dihydropteridinones: wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients...

20060035905 - Formulations of phosphodiesterase 5 inhibitors and methods of use: The present invention provides compositions and delivery methods to enhance treatment for sexual dysfunction or hypofunction through the delivery of phosphodiesterase 5 inhibitors to a mammal. Phosphodiesterase 5 inhibitors are one example of a compound class used for this indication. Examples of compounds in this class include taldalafil and vardenafil...

20060035906 - Process for production of 1-[2-(benzimidazol-2-yl- thio)ethy]piperazine or salts thereof: e

20060035907 - Methods of treating abnormal cell growth using c-met and m-tor inhibitors: The invention provides a method of treating abnormal cell growth in a mammal, such as a human, by administering to the mammal a therapeutically effective amount of a c-MET inhibitor and a mammalian target of rapamycin (mTOR) inhibitor....

20060035908 - Thienopyrimidines useful as aurora kinase inhibitors: wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of...

20060035909 - Azapurine derivatives: The invention further relates to the use of said compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi...

20060035910 - Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal...

20060035911 - Method of improved diuresis in individuals with impaired renal function: Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or...

20060035912 - Pyrrolopyrimidine derivatives useful in cancer treatment: or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof, wherein L, R1, R2 R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating abnormal cell growth, such as cancer in a mammal by administering...

20060035914 - Compositions and methods for the treatment of disorders of the central and peripheral nervous systems: The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for...

20060035913 - Method for the production of 2-amino-4-chloro-6-alkoxypyrimidines: The present invention provides a process for preparing 2-amino-4-chloro-6-alkoxypyrimidines by reacting the 2-amino-4,6-dichloropyrimidine with an alkali metal alkoxide or a mixture of alkali metal hydroxides and an alcohol, in which the reaction is effected in a polar aprotic solvent (or solvent mixture), the solvent is subsequently distilled off to an...

20060035915 - Non-sedating barbituric acid derivatives: The present invention relates to novel non-sedating barbituric acid derivatives, pharmaceutical compositions containing them and methods of neuroprotection in cases of cerebral ischemia, head trauma and other acute neurologic injuries, and prevention of resulting neuronal damage. The invention also relates to the use of non-sedating barbituric acid derivatives given in...

20060035916 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized...

20060035917 - Medicament component of berberine for the use of prevention and treatment of psycological dependence on and analgesic tolerance to morphine: Disclosed is a pharmaceutical composition for preventing and treating addiction to morphine or preventing and inhibiting the development of tolerance to the analgesic effects of morphine, containing berberine as an effective ingredient, wherein the berberine has an inhibitory effect versus psychological dependence on abused drugs such as morphine and the...

20060035919 - Tetracylic immunomodulatory compounds: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly, the present...

20060035918 - Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma: A method for treating or prevent acute or chronic asthma is disclosed, comprising administering effect amounts of an FK506 derivative and a β2-agonist to a human being or an animal. A composition comprising an FK506 derivative and a β2-agonist as a combined preparation is also disclosed...

20060035920 - Chk-1 inhibitors: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy....

20060035921 - N3-substituted imidazopyridine c-kit inhibitors: s

20060035922 - Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors:

20060035923 - Overactive bladder treating drug: A therapeutic agent for overactive bladder containing tamsulosin or a pharmaceutically acceptable salt thereof as an effective ingredient....

20060035926 - Benzothiazolium compounds: t

20060035927 - Calcilytic compounds: Novel methods of treating bone diseases or disorders are provided....

20060035928 - Combination therapeutic compositions and methods of use: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, α-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy...

20060035924 - Daily melatonin dosing units: The present invention relates to a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect....

20060035925 - Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof: wherein R1-R5, A, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in...

20060035929 - Combination therapeutic compositions and methods of use: Combination therapies of substituted quinolines and substituted diphenyl sulfones are disclosed. More specifically, compositions containing substituted quinolines and substituted diphenyl sulfones are disclosed. In addition, methods of using the compositions in the treatment of neurodegenerative disorders, including, inter alia, Alzheimer's dementia, HIV-1 associated dementia, and Creutzfeld-Jakob disease are also disclosed....

20060035930 - 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted -amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors: m

20060035931 - Crystalline form of a biphenyl compound: The invention provides a crystalline 1,2-ethanedisulfonic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also provides pharmaceutical compositions comprising such a salt or prepared using such a salt; processes and intermediates for preparing such a salt; and methods of using such a salt to treat...

20060035933 - Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1, R2, R4, R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds...

20060035932 - N-aryl piperidine compounds: The present invention provides N-aryl piperidine compounds having antiinfective activity (i.e., antibacterial, antiviral), their compositions and methods of use. The compounds of the invention prevent the entry of HIV into host cells. More particularly, the compounds are effective at in inhibiting the binding interaction of HIV glycoprotein gp120 and the...

20060035934 - Fused compounds that inhibit vanilloid subtype 1 (vr1) receptor: e

20060035935 - Acylated piperidine derivatives as melanocortin-4 receptor agonists: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual...

20060035936 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor....

20060035937 - (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate: The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt....

20060035938 - 2-pyridone derivatives as inhibitors of neutrophile elastase: There are provided novel compounds of formula (I) wherein R1?, R4?. R5?, G1?, G2?, X, L, Y1?, Y2? and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use...

20060035939 - 3-aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (vr1) activity: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group...

20060035940 - (s)-amlodipine malate: One aspect of the present invention relates to optically pure (S)-amlodipine malate. Another aspect of the present invention relates to (rac)-amlodipine malate. In a preferred embodiment, the compound is optically pure (S)-amlodipine L-malate. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine malate. Another...

20060035941 - Calcium salts of indole derived statins: The present invention provides calcium salts of indole derived statins of the formula (IA) wherein R1, is alkyl, cycloalkyl or aralkyl; R2, R3 and R4 are independently hydrogen, halogen or alkyl; R5 and R6 are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the...

20060035942 - Fungicidal combinations of active substances: e

20060035943 - 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith....

20060035944 - Remedies for neurodegenerative diseases: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is {circle around (1)} a fused polycyclic heteroaryl group wherein the ring...

20060035945 - Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or...

20060035946 - Amyloid-binding, metal-chelating agents: The present invention relates to the diagnosis, prevention, and treatment of pathophysiological conditions associated with amyloid accumulation. Bifunctional therapeutic molecules and contrast imaging agents exhibiting a high affinity for amyloid deposits, and pharmaceutical compositions thereof are described. The invention also provides methods of using these bifunctional molecules, contrast imaging agents,...

20060035947 - Pesticidal composition: e

20060035948 - Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them: The present invention relates to benzopyran derivatives substituted with secondary amines including tetrazole, method for preparing thereof and pharmaceutical compositions containing them. The compounds of the present invention can be used for protecting neuronal cells and brain damage; antioxidation; inhibiting NO generation; protecting heart; suppressing angiogenesis; protecting preserving organs such...

20060035949 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents: or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are...

20060035950 - Novel processes for preparing substantially pure anastrozole: The present invention provides novel processes for purifying anastrozole, devoid of using liquid chromatography. The purification processes are via the isolated anastrozole salt forms, either by crystallization or by selective acidic extractions, and optionally in both cases, converting the purified anastrozole salt to anastrozole base. Also provided is an improved...

20060035951 - N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors: e

20060035952 - Photosensitizer formulations and their use: A low concentration formulation for hydrophobic photosensitizers (PS) and improved method for photodynamic therapy (“PDT”). It was found that PDT treatments using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. It was found that the inventive formulation (1) reduces the time for a...

20060035954 - Ammonolysis process for the preparation of intermediates for dpp iv inhibitors: l

20060035953 - Process and intermediates for the preparation of the thienopyrrole derivatives: A process for preparing a compound of formula (I) where R4 and R5 are as defined in the specification; and R6 is hydrogen or a protecting group, which process comprises cyclisation of a compound of formula (II) where R4, R5 and R6 are as defined in relation to formula (I),...

20060035955 - Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of...

20060035956 - Indole derivatives comprising an acetylene group: and X, R1 to R12, m, n and o are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention is also directed to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases...

20060035957 - Preventive or remedy for bedsore: In accordance with the present invention, there are provided a preventive or of preventing or therapeutic agent for decubitus comprising an N-acylated derivative of hydroxyproline or a salt thereof; the above preventive or therapeutic agent wherein the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount...

20060035958 - Method of treating diabetes and related conditions: The present invention addresses the use of substituted thiophene derivatives, as well as compositions containing such compounds for treating type 2 diabetes mellitus. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose...

20060035959 - Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds: Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds corresponding to formula I, as well as to their use in the production of drugs and in related methods of treating or inhibiting pain and neurodegenerative disease....

20060035960 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents: or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are...

20060035961 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents:

20060035962 - Method and compositions for preparing a compound using a benzoylating agent essentially free of ring chlorination: This invention relates to methods and compositions for preparing compounds using a benzoylating agent essentially free of ring chlorination. In one alternative embodiment, the present invention relates to methods and compositions for preparing taxanes essentially free of ring chlorinated impurities. In another alternative embodiment, the present invention comprises methods of...

20060035963 - Quinone prodrug compositions and methods of use: The present invention relates to quinone prodrug compositions and therapeutic methods using such prodrug compositions. Preferably, the quinone compounds of the invention are napthoquinone compounds such as β-lapachone or β-lapachone analogs. The quinone prodrug compositions of the invention exhibit improved solubility, stability, bioavailability, and pharmacokinetic properties, as well as improved...

20060035964 - Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan: Drugs containing Taxiresinol, (7′R)-7′-Hydroxylariciresinol, Secoisolariciresinol and Isotaxiresinol, which are lignans contained in Hongdoushan, as the active ingredients. Drugs containing an extract, which is obtained by extracting a Hongdoushan plant with water and further extracting the obtained extract with an organic solvent, as the active ingredient. These drugs are useful particularly...

20060035965 - Selective androgen receptor modulators and methods of use thereof: This invention provides SARM compounds and their use in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder....

20060035966 - Irreversible selective androgen receptor modulators and methods of use thereof: In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds...

20060035967 - Novel phthalamide derivatives: Novel phthalamide derivatives of the formula (I) (I) wherein R1, R2, R3, R4, and R5 have the meanings given in the description, processes for their preparation, and their use as insecticidal agents in agricultural and horticultural field....

20060035968 - Composition for preventing cancer comprising 2'-benzoyl-oxycinnamaldehyde: Disclosed is a composition for preventing cancer comprising a compound represented by Chemical Formula 1, 2′-benzoyloxycinnamaldehyde (BCA). BCA has the effects of delaying tumor incidence and increasing immune cells in a transgenic mouse overexpressing H-ras oncogene playing a critical role in tumor cell growth. Thus, BCA is useful as a...

20060035969 - Novel modulators of the ppar-type receptors and cosmetic/pharmaceutical compositions comprised thereof: s

20060035970 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed....

20060035971 - Blood fluidity improving agent: A blood fluidity-improving agent, a blood circulation promoter or a cerebrovascular disease-improving agent, containing as an active ingredient thereof one or more ingredients selected from the group consisting of chlorogenic acids, caffeic acids, ferulic acids and pharmaceutically acceptable salts of these acids. The present blood fluidity-improving agent, blood circulation promoter...

20060035972 - Therapeutic compositions and uses: The invention provides compositions for and methods of treating a number of disorders. In one embodiment, the invention provides a method of treating a wide range of conditions by administering to a human being in need of such treatment, a therapeutically effective amount of (a) N-6-trimethyl-L-lysine of at least 98%...

20060035974 - Linoleic acid active agents for enhancing probability of becoming pregnant: The present invention is directed to a methods and compositions for enhancing the probability that a subject will become pregnant. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a linoleic acid active agent, e.g., linoleic acid, a polyunsaturated fatty acid analog thereof, etc....

20060035973 - Pharmaceutical composition for intracellular acidification with cis-urocanic: A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is...

20060035975 - Enteric coated oral pharmaceutical to erode kidney stones: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic...

20060035976 - Methods of preventing headaches with norepinephrine precursors: The present invention relates to methods of preventing headaches in a subject in need thereof, comprising, administering effective amounts of a norepinephrine precursor, threo-3-(3,4-dihydroxyphenyl)serine, a derivative thereof, or a pharmaccutically-acceptable salt thereof. The methods can be used to prevent migraine, tension-type, premenstrual, and other types of headaches....

20060035977 - Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f: The invention relates to the use of molecules, particularly in the fields of human and veterinary health and cosmetics. The inventive compounds are acylated aminopropanediols and the nitrogen- and sulfur-containing analogues thereof and have advantageous pharmacological and cosmetic properties. In particular, the inventive compounds can be used to prevent and/or...

20060035978 - N-cyano-n-methyl-imidamide derivatives: e

20060035979 - Inhibitors of transcription factor nf-kappab: The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory...

20060035980 - Thyronamine derivatives and analogs and methods of use thereof: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed....

20060035981 - Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment: This invention discloses a method and formulation for treatment/prevention of human and animal cancers. The invention is designed to exploit the vulnerability of cancer with regards to its anaerobic requirement for non-oxidative phosphorylation of glucose to derive energy, which is opposite to the host. The composition is comprised of a...

20060035982 - Method for promoting blood stream: i

20060035983 - Methods for treating fungal infections: A method of treating a mycotic infection (particularly onychomycosis) of a nail of a subject in need thereof comprises topically applying to a nail of the subject an effective antimiycotic amount of a fungicidal compound of the formula R—(O—CH2—CH2)n—OH, wherein R is a saturated hydrocarbon or alkyl group. Compositions for...

20060035984 - Method of inhibiting formation of neisseria gonorrhea and neisseria meningiditis: The present invention provides a method of inhibiting the formation of pseudorabies particles in a host cell. The method involves administering an effective amount of a poly-hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of reducing or inhibiting the growth...

20060035985 - Compositions for inhibiting the scent tracking ability of mosquitoes in environmentally defined three dimensional spaces: wherein R1 and R2 are each independently a saturated or unsaturated aliphatic hydrocarbon group containing from 1 to about 12 carbon atoms, in a vehicle base that is a porous or waxy medium. The composition being capable of dispensing the inhibiting compound in an non-lethal amount effective to inhibit the...

20060030517 - Anti-cancer agent: The invention relates to an anti-cancer agent containing α-chain protein (α-fragment) of HGF (hepatocyte growth factor) as an active ingredient. The active ingredient of α-fragment has a specific suppressing effect on invasion and metastasis of cancer cells such as gallbladder cancer, lung cancer and other, which are highly metastatic and...

20060030518 - Acylated insulin: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a)...

20060030519 - Composition for reducing blood lipids: A composition for reducing the blood lipids is disclosed. The composition includes the lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium...

20060030520 - Gdf3 propeptides and related methods: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with...

20060030521 - Remodeling and glycoconjugation of peptides: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide....

20060030522 - Alk7 and myostatin inhibitors and uses thereof: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke,...

20060030525 - Apolipoprotein a-i derivatives with altered immunogenicity: The present invention relates to novel apolipoprotein A-I proteins with altered immunogenicity....

20060030528 - Compositions and methods for treating peripheral vascular disease: The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom....

20060030530 - Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases: The present invention is drawn to methods of screening for new compounds for the treatment of obesity and obesity-related diseases and disorders, as well as methods of treating obesity-related diseases and disorders, based on the discovery of the role of the leptin-LSR interaction in obesity....

20060030531 - Pharmaceutical composition comprising factor vii polypeptide and pai-1 polypeptide: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and PAI-1 or a PAI-1-related polypeptide, and the use thereof for treating bleeding episodes....

20060030527 - Rage fusion proteins and methods of use: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity...

20060030523 - Sclerostin and the inhibition of wnt signaling and bone formation: The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt...

20060030526 - Stable suspension formulations of erythropoietin receptor agonists: A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle....

20060030524 - Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens: Systemic lupus erythematosus (SLE) can be prevented or treated by down-regulating the autoimmune response to the C-terminal-DNA-binding domain of the p53 protein (p53) by an active principle selected from the group consisting of: (i) a peptide of, or comprising, the C-terminal DNA-binding domain of the p53 protein; (ii) a monoclonal...

20060030529 - Use of vegf inhibitors for treatment of eye disorders: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy....

20060030532 - Novel antimicrobial compounds: The invention features an antimicrobial composition comprising a substance P peptide and methods of inhibiting growth of a microorganism by contacting the microorganism with a substance P peptide. Bacterial and fungal pathogens are inhibited by the substance P compositions....

20060030533 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds....

20060030537 - Ceramide kinase and uses thereof: The invention relates to a method of inhibiting the production of ceramide-1-phosphate in a cell by delivering to the cell a ceramide kinase antagonist. The invention also relates to a method of treating a condition related to activation of phospholipase A2 in a subject by administering to the subject a...

20060030536 - Combination therapies for cancer and proliferative angiopathies: Compositions and methods for treating cancer and proliferative angiopathies are provided. A composition can include an inhibitor of the Jak2/Stat3 signaling pathway and an inhibitor of the PI3k/Akt signaling pathway. In certain cases, the two inhibitors are capable of acting synergistically as compared to either inhibitor alone....

20060030535 - Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics: Materials and methods are provided to modulate, in a controlled manner, the pharmacokinetic and biodistribution properties of nucleic acid aptamers, and to enhance their safety and efficacy properties as therapeutic agents....

20060030541 - Genes involved in osteogenesis, and methods of use: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 2, 7, 22, 25, 33, 35, 37, 38, 42, 47, 64, 69 or...

20060030538 - Methods for reducing or preventing localized fibrosis using sirna: Methods for reducing or preventing localized fibrosis in a localized tissue region using SiRNA technology....

20060030539 - Product and process for inhibition of biofilm development: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing...

20060030540 - Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent: The present invention is directed toward a method of producing transgenic animals by administration of a composition to an animal via a natural gastrointestinal pathway. The composition achieves widespread distribution, systemic expression and sustained delivery in the animal. More particularly, the invention discloses a method for producing a transgenic animal...

20060030534 - Treatment of neurological disorders by dsrna administration: The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein said dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment....

20060030542 - Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor through administration of a pyrophosphate analog: Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor by administering a pyrophosphate analog. Methods and compositions for protecting a pharmacological agent in a formulation, comprising combining the pharmacological agent with at least one pyrophosphate analog. Methods and compositions for increasing...

20060030543 - Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease: Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of...

20060030544 - Protein kinase and phosphatase inhibitors and methods for designing them: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may...

20060030545 - Anti-proliferative compounds, compositions, and methods of use thereof: e

20060030547 - Antineoplastic combinations: This invention provides the use of a combination of CCI-779 and an antineoplastic alkylating agent in the treatment of neoplasms....

20060030546 - Organo-phosphorous compounds for activating gamma/delta t cells: i

20060030548 - Methods of using ryanodine antagonists in treating neural injury: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a ryanodine antagonist, e.g. dantrolene, to inhibit or prevent nerve cell injury or death....

20060030549 - Paricalcitol(zemplar) capsule controls secondary hyperparathyroidism (shpt) in ckd stage 5 patients: Oral paricalcitol for sustained reduction of parathyroid hormone in dialysis patients....

20060030550 - Pharmaceutical formulations: Disclosed are medicaments containing, separately or together, (A) Pleconaril or a pharmaceutically acceptable salt thereof and (B) a pharmaceutically active agent for simultaneous, sequential or separate administration in the treatment of a viral infection and/or other disease states and the symptoms associated therewith....

20060030551 - Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs: Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the...

20060030552 - Process for the preparation of 7alpha-alkylated 19-norsteroids: Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant....

20060030553 - Cell adhesion inhibitors: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and...

20060030554 - Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease: or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which...

20060030555 - Novel imidazopyridines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060030556 - Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency: The invention relates to the use of neurokinin-1 receptor antagonists as testosterone replacement therapy. In a further aspect the invention relates to the use of neurokinin-1 receptor antagonists for the preparation of medicaments for treating conditions associated with low testosterone levels, in patients having deficient testosterone levels. In another aspect...

20060030557 - Substituted pyridines having antiangiogenic activity: e

20060030558 - Novel compounds as opioid receptor modulators: This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders....

20060030559 - Diazole derivatives: wherein A, E, R1, R2 and R3 are as defined in application and pharmaceutical compositions containing them. The invention also relates to use of such compounds for the treatment of diseases mediated by the metabotropic glutamate receptors (mGluR), such as anxiety, chronic and acute pain, protection against liver damage, urinary...

20060030560 - Pyrimidine compounds: each of R2 and R4 is H; R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is NRc; Y is covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc;...

20060030561 - Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof: wherein R1, R2, R3, R4, R5, and R6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory,...

20060030562 - Use of an inhibitor of cathepsin-s-or-b to treat or prevent chronic obstructive pulmonary disease: This invention is directed to the use of an inhibitor of cathepsin-S or -B, or composition thereof to treat or prevent chronic obstruction pulmonary disease, or physiological condition associated therewith. Such a therapy would occur using at least one of such inhibitors alone or in combination with the other, or...

20060030563 - Novel pyrazole analogs acting on cannabinoid receptors: One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the CB1 cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and...

20060030564 - Inhibitors of akt activity: The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention....

20060030565 - Amide derivatives and nociceptin antagonists: wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by...

20060030566 - Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders: e

20060030567 - Cyclopropyl-thienyl-carboxamide as fungicides: A fungicidally active compound of formula (I): where X is (X1), (X2) or (X3); Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that the ring is not 1,2,3-triazole, the ring being substituted by groups R4, R5...

20060030568 - Crystal modificaion of a n-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use: The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumour therapy....

20060030569 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof: e

20060030570 - Method for treating cryptorchidism: The present invention relates to a method and pharmaceutical composition for the treatment of male individuals suffering from cryptorchidism comprising administering to said individuals an effective amount of an aromatase inhibitor, preferably finrozole....

20060030571 - Ecteinascidins: The present invention is directed to several newly discovered ecteinascidin (Et) species, designated herein as Et 731, Et 745B, Et 815, Et 808, Et 596, Et 597, Et 583, Et 594 and a synthetic derivative of Et 594, N-Acetyl Et 597. The physical properties of these compounds, their preparation and...

20060030572 - Method of improved diuresis in individuals with impaired renal function: Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or...

20060030573 - Substituted quinazolinone compounds: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein....

20060030574 - Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors: In accordance with the present invention there is provided a method for the treatment of peripheral arterial diseases in a host comprising administering a therapeutically effective amount of compounds having the formulas (I) through (III) or analogues thereof....

20060030576 - Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto:

20060030575 - Integrin alpha-v beta-3 antagonists for use in imaging and therapy: Integrin receptor antagonists whose molecular structure includes a tetrahydropyridimidinylaminoethyloxybenzoyl group on a sulfonylamino-β-alanine nucleus exhibit increased binding affinity for the αvβ3 receptor when further substituted on the sulfonyl moiety with an N-amino alkycarbamyl group or a butyloxycarbonylamino alkylcarbamoyl group or similar groups....

20060030577 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders: wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse,...

20060030578 - Pharmaceutically active lipid based formulation of irinotecan: Delivering therapeutic amounts of irinotecan remains limited due to its highly water insoluble properties. This invention overcomes this limitation by presenting a novel method of preparing liposomal irinotecan by first inactivating irinotecan prior to liposome formation and then subsequently activating the irinotecan by lowering the pH of the lipid composition...

20060030579 - Compounds for the treatment of proliverative processes: The invention relates to the use of anticholinergics for preparing a pharmaceutical composition for the prevention and treatment of proliferative processes....

20060030580 - Method for decreasing opioid metabolism: e

20060030584 - 2,8-disubstituted naphthyridine derivatives: and pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, R3, R21, A1, A2, X, and Z are as defined herein. Compounds of formula A are useful in the treatment of diseases and/or conditions related to cell differentiation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical...

20060030581 - Mannitol formulation for integrin receptor antagonist: Disclosed are pharmaceutical compositions of an integrin αvβ3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget's disease....

20060030583 - Pyrrolo-pyridine kinase modulators: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity....

20060030582 - Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity: e

20060030585 - Tricyclic delta-opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described....

20060030586 - Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation: e

20060030587 - Method of treating attention deficit disorders with d-threo methylphenidate: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof....

20060030588 - Heteroaryl urea neuropeptide y y5 receptor antagonists: t

20060030589 - Substituted n-acyl-2-aminothiazoles:

20060030590 - Alkyl-and piperidine-substituted benzimidazole derivatives:

20060030593 - 1-heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor....

20060030591 - Crystalline polymorph of pipindoxifene hydrochloride monohydrate: The present invention is directed to a crystalline polymorph of pipindoxifene hydrochloride monohydrate, compositions containing the same, preparations thereof, and uses thereof....

20060030592 - I-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels: 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4- and/or 7-position of the isoindoline ring and optionally further substituted in the 3-position of the 2,6-dioxopiperidine ring reduce the levels of inflammatory cytokines such as TNFα in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline...

20060030594 - Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and...

20060030595 - Potassium channel inhibitors: t

20060030596 - Nf-kappab inhibitors: The present invention provides novel compounds and methods for treating diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB....

20060030597 - Method of inhibiting angiogenesis: Angiogenesis is inhibited and the growth of tumors is treated by administering an effective amount of a PPAR gamma ligand/agonist, optionally with an RXR receptor ligand....

20060030598 - Thiazolyl inhibitors of tec family tyrosine kinases: Novel thiazolyl compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of Tec family tyrosine kinase-associated disorders such as cancer, immunologic disorders and allergic disorders....

20060030599 - Sulphonamide derivatives: R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C) chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl,...

20060030600 - Dual nk1/nk3 receptor antagonists for the treatment of schizophrenia:

20060030601 - Novel aminopyridine derivatives as mglur5 antagonists: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group. The compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors....

20060030602 - (s)-amlodipine malate: One aspect of the present invention relates to optically pure (S)-amlodipine malate. Another aspect of the present invention relates to (rac)-amlodipine malate. In a preferred embodiment, the compound is optically pure (S)-amlodipine L-malate. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine malate. Another...

20060030603 - Novel aryl urea analogs and use thereof as antibacterial agents: e

20060030604 - Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators: The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II...

20060030606 - Cyclohexyl prostaglandin analogs as ep4-receptor agonists: e

20060030605 - Pharmaceutical compounds: Compounds or their salts having general formulas (I) and (II) wherein: s=is an integer equal to 1 or 2, preferably s=2; b0=0 or 1; A is the radical of a drug and is such as to meet the pharmacological tests reported in the description, C and C1 are two bivalent...

20060030607 - Compounds for the reduction of excessive food intake: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake....

20060030608 - Anti aromatase compounds pharmaceutical compositions and uses thereof: wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating estrogen receptor activity in a cell or patient or treating an estrogen receptor-mediated disorder, particularly...

20060030609 - Oxazolidinones containing oxindoles as antibacterial agents: e

20060030610 - Method of treating inflammatory diseases: Disclosed are methods of treating inflammatory diseases and disorders, such as arthritis and inflammatory bowel disease, in mammals....

20060030611 - Enoximone sulfoxide enantiomers and their use in the treatment of pde-iii mediated diseases: The present invention provides the (R)-(+) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (R)-(+) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial....

20060030612 - Indazoles useful in treating cardiovascular diseases: e

20060030613 - Indole, indazole and indoline derivatives as cetp inhibitors:

20060030614 - Carvedilol: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof....

20060030615 - Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof: Pyrrole-oxindole derivatives useful as progesterone receptor antagonists are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions....

20060030616 - Anhydride modified cantharidin analogues useful in the treatment of cancer: Anhydride modified cantharidin analogues useful in the treatment of certain forms of cancer also methods for the screening for anti-cancer activity of these analogues and/or their ability to sensitise cancer cells to cancer treatment. The modified cantharidin analogues have structure (I) or (II), wherein R1, R2, R3 and R4 are...

20060030617 - Compounds useful for the treatment of cancer, compositions thereof and methods therewith: The present invention generally relates to compounds and compositions useful for the modulation of ligase activity. The invention further relates to Compounds of the Invention, compositions thereof, and methods for treating or preventing cancer, a neoplastic disorder, acute or chronic renal failure, an inflammatory disorder, an immune disorder, a cardiovascular...

20060030618 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic...

20060030619 - Compositions and methods for chelation therapy: The invention relates to compositions and methods of treatment using an iron chelator, an antioxidant, estrogen, and/or combinations thereof, optionally, linked to a nanoparticle, to treat a subject in need thereof. The compositions and methods may be used to restore or protect the normal functions of osteoblast and osteoclast by...

20060030620 - Method for treating and/or preventing ischemia/reperfusion injury: Magnesium ascorbate, a previous Romanian cardio protective drug, is provided to alleviate ischemia/reperfusion injury. In particular, the present invention relates to a pharmaceutical composition of magnesium ascorbate for treating and/or preventing liver ischemia/reperfusion injure in mammals....

20060030621 - Preparation for external use on skin: The present invention has as an object to provide a preparation for external use on skin in which the percutaneous absorption amount of ascorbic acid or an ascorbic acid derivative is increased and an effect on improving skin pigmentation and dullness is enhanced. In a preparation for external use on...

20060030622 - Compounds and methods for the treatment of urogenital disorders: The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic...

20060030623 - Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis: or its pharmaceutically acceptable salt has excellent antidiabetic effect, anti-obesity effect and anti-arteriosclerosis effect, a medicine containing the compound of formula (1) as the active ingredient is useful as an agent for the prevention or treatment of diabetes (especially non-insulin dependent diabetes mellitus), obesity (especially visceral fat obesity), or arteriosclerosis....

20060030624 - Anticancer agents based on prevention of protein prenylation: Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. α-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be...

20060030625 - Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters: Dietary supplements for treating a neurotransmitter deficiency include one or more precursors of the deficient neurotransmitter and a cofactor for activating in vivo enzymatic synthesis of the deficient neurotransmitter. The dietary supplements can also include an appropriate neurotransmitter, such as an amino acid. When administered through the oral mucosa, increases...

20060030626 - Method of treating autoimmune diseases: A method of treating an autoimmune disease comprising administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof....

20060030627 - Bioabsorbable granular porous bone filling material and production method thereof: A bioabsorbable granular porous bone filling material having a particle diameter 100 to 3000 μm used for filling a defect part after removing a lesion, or grafting a self bone, and for reinforcing or filling a jawbone when embedding a dental implant, is produced such that the polymer material containing...

20060025329 - Compositions and methods for inhibiting cellular proliferation comprising tfpi fragments: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase...

20060025328 - Compositions suitable for controlled release of the hormone gnrh and its analogs: A liquid composition for the controlled release of gonodotropin releasing hormone (GnRH) or its analogs or agonists is provided that includes: (i) a non-polymeric, non-water soluble liquid carrier material (HVLCM) of viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions;...

20060025330 - Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon: The present invention provides an electrostatic bonding macromolecular micelle drug carrier comprising a block copolymer having a non-chargeable segment and a chargeable segment, for stably carrying a chargeable drug tending to be easily decomposed in vivo such as protein and DNA....

20060025327 - Hybrid molecules qa, wherein q is an aminoquinoline and a is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent: e

20060025326 - Method for treating carrier particles and its use: A method for treating a particulate carrier for an inhalation powder improving the stability and flowing properties of the carrier. The carrier is abraded suspended in a liquid medium, in which the carrier is essentially insoluble, the liquid medium is evaporated and the carrier recovered....

20060025331 - Vascular endothelial growth factor 2: Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound...

20060025332 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds....

20060025333 - Inhibition of histone deacetylase as a treatment for cardiac hypertrophy: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by...

20060025343 - Angiogenically effective unit dose fo fgf and method of adminstering: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition...

20060025340 - Cerberus/coco derivatives and uses thereof: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives....

20060025338 - Compositions and methods for treatment of lymphatic and venous vessel arterialization: The present invention is directed to methods and compositions that may be used in disrupting the association of smooth muscle cells with lymphatic endothelial cells and in correcting the valvular dysfunction in veins and lymphatic vessels. Such compositions are useful for therapeutic and prophylactic treatment of impaired lymphatic and venous...

20060025339 - Corticotropin releasing factor 2 receptor agonists: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy....

20060025341 - Follistatin-3: The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The...

20060025335 - Netrin compositions and methods of using the same: The present invention provides methods and compositions to modulate inflammation and inflammatory responses using Netrin polypeptides and Netrin receptors. Methods of the present invention comprise the use of Netrin polypeptides and Netrin receptors to decrease migration of inflammatory cells of the immune system to a site of injury or infection....

20060025336 - Pharmaceutical compositions comprising combinations of factor vii polypeptides and aprotinin polypeptides: Compositions comprising factor VII or a factor VII-related polypeptide and aprotinin or an aprotinin-related polypeptide and uses thereof are provided....

20060025337 - Sirtuin related therapeutics and diagnostics for neurodegenerative diseases: Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contacting a cell with an activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin;...

20060025342 - Treatment of bone disorders with skeletal anabolic drugs: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety....

20060025334 - Vanilloid receptor-2 ligands for treating anxiety or depression: The present invention relates to the use of a compound selected from: (a) a VR2 polypeptide; (b) a compound which modulates the activity of a VR2 polypeptide; (c) a polynucleotide encoding a VR2 polypeptide; or (d) an antisense polynucleotide to a polynucleotide encoding a VR2 polypeptide, for the manufacture of...

20060025344 - Ghrelin receptor inverse agonists for regulation of feeding behaviors: Compounds of the invention act as inverse agonist ghrelin receptors. Some of the compounds of the invention may have both inverse agonistic and antagonistic properties as they both decrease or eliminate the constitutive activity of he ghrelin receptor and block the effect of ghrelin. Other preferred compounds of the invention...

20060025347 - Iap binding compounds: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using...

20060025346 - Permeability enhancer: The present invention provides an enhancer for the absorption by membrane permeation of low molecular weight substances. An enhancer for the absorption of low molecular weight substances by membrane permeation comprising poly-γ-glutamic acid as an active ingredient, and a composition characterized by comprising poly-γ-glutamic acid and a functional food component...

20060025345 - Substituted ethane-1,2-diamines for the treatment of alzheimer's disease: e

20060025348 - Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production: The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial...

20060025351 - Cancer treatment including glycolytic inhibitors: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments...

20060025349 - D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture: y

20060025352 - Glucopyranosyloxypyrazole derivatives and use thereof in medicines: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom;...

20060025350 - Oligosaccharide derivative: wherein A represents a group such as a cyclic group, R1 and R2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or...

20060025353 - Insulin secretion by anthocyanins and anthocyanidins: A method for stimulating insulin secretion by anthocyanidins and anthocyanins is described. The secretion can be in vivo in mammals, including humans, or in vitro....

20060025354 - Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia: A method for the treatment of obesity, diabetes, high cholesterol and related diseases including hyperglycemia, lipid disorders, hyperglyceridemia, dyslipidemia and atherosclerosis in mammals using anthocyanins, anthocyanidins, ursolic acid and/or betulinic acid is described. Compositions adapted for these treatments are also described....

20060025355 - Compositions comprising amphotericin b, methods, and systems: A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about...

20060025356 - 28-epirapalogs: Methods and materials involving 28-epirapamycin analogs are disclosed....

20060025357 - Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus: The present invention relates to agent for suppressing infection and proliferation of human immunodeficiency syndrome virus (HIV-1), which infects immunocompetent cells such as macrophage or dendritic cell and causes destruction of immune system, and use of known compounds, macrolide derivatives for suppression of infection and proliferation of human immunodeficiency syndrome...

20060025358 - Treatment and prevention of th1 and 'autoimmune' diseases effected with antibiotics and/or angiotensin inhibition: This invention is a method of killing the stealthy intra-cellular bacteria which cause many Th1 and ‘Autoimmune’ diseases. The methods described in this invention will treat and prevent the diseases customarily named Diabetes Type 1, Diabetes Type 2, Rheumatic Arthritis, Reactive Arthritis, Osteo Arthritis, Psoriasis, Scleroderma, Osteoporosis, Atherosclerosis, Myocarditis, Endocarditis,...

20060025359 - Composition and method for treating graft-versus-host disease: Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute...

20060025367 - Adenovirus vectors encoding brain natriuretic peptide: The invention provides isolated and purified nucleic acid molecules encoding a natriuretic peptide useful in methods to inhibit or prevent heart failure....

20060025372 - Antisense modulation of ptp1b expression: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided....

20060025368 - Growth hormone releasing hormone enhances vaccination response: This invention discloses compositions and methods of: vaccinating a subject; enhancing the vaccination efficiency; preparing a subject prior to vaccination response; and improving the clinical outcome after infectious challenge in a subject that has been vaccinated. More specifically, the invention pertains to delivering into a tissue of the subject a...

20060025362 - Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation: The present invention relates to a recombinant protein consisting of Guanylate Binding Protein-1 (GBP-1), or one or more functional parts thereof, linked to a shuttle protein. The present invention also relates to an expression vector comprising the Guanylate Binding Protein 1 (GBP-1) gene or parts thereof. The introduction of said...

20060025360 - Human cervical cancer protooncogene and protein encoded therein: A human cervical cancer 1 protooncogene having a base sequence of SEQ ID:1 or a fragment thereof is overexpressed in various cancer tissues and can be used in diagnosing various cancers and an anti-sense gene complementary thereto can be used in treating cancers....

20060025365 - Immunostimulatory oligonucleotide multimers: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary....

20060025366 - Immunostimulatory sirna molecules and uses therefor: The present invention provides siRNA molecules and methods of using such siRNA molecules to modulate an immune response and to silence expression of a target gene....

20060025371 - Methods of inhibiting cox-2: The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for COX-2, and further provides methods of reducing expression of COX-2 in cells (e.g., cancer cells)....

20060025369 - Methods of inhibiting manganese-containing superoxide dismutase 2 (mnsod): The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for MnSOD, and further provides methods of reducing expression of MnSOD in cells (e.g., cancer cells)....

20060025370 - Methods of inhibiting vegf-c: The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells)....

20060025373 - Modulation of glucocorticoid receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor...

20060025374 - Novel oligoribonucleotide derivatives for specific inhibition of gene expression: The present invention relates to oligoribonucleotide derivatives which have a 2′5′-linked oligoribonucleotide residue without a 5′-phosphate residue on the 3′ end and to the use thereof for specific inhibition of gene expression....

20060025364 - Regulation of peritoneal healing and adhesion development: Methods for the prevention of adhesion formation and development, and for the stimulation of fibrosis, involve the administration of therapeutic formulations to a patient containing inhibitors or stimulators to selected molecular adhesion markers. The molecular markers of the invention include Caspase 2, Caspase 3, Caspase 9, PPARα, PPARβ, PPARγ1, PPARγ2,...

20060025361 - Rna interference mediated inhibition of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression...

20060025363 - Use of antisense oligonucleotides for the treatment of degenerative skin conditions: A pharmaceutical or cosmetic composition for topical application containing one or more oligonucleotides which are capable of hybridizing with a mRNA or a gene sequence which codes for a connective-tissue decomposing enzyme, or a physiologically compatible salt thereof. The compositions are suitable in particular for the treatment of degenerative skin...

20060025375 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The...

20060025376 - Uridine effects on dopamine release: The present invention provides methods for increasing secretion of dopamine and other neurotransmitters and treating or reducing the incidence of diseases involving decreased secretion of dopamine and other neurotransmitters, e.g. Parkinson's disease, comprising administering to the subject a uridine or a source thereof, and compositions for treating or reducing an...

20060025378 - Dose dependent elimination of ha and cell receptor stimulation: The invention provides a method to alter elimination kinetics of hyaluronic acid (HA) in a patient is disclosed. Administration of HA to a patient, followed by at least one subsequent administration results in an alteration of the ability of the patient to eliminate HA. Also disclosed is a method for...

20060025377 - Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor: The inhibitor of angiogenesis is characterized by containing tetraacetylphytosphingosine and the kit for inhibiting angiogenesis is characterized by the inhibitor. The inhibitor and kit are effective in treating and preventing disorders in connection with extremely increased angiogenesis such as angioma, tumor and psoriasis by effectively inhibiting angiogenesis. Furthermore, they are...

20060025379 - Small molecule stimulators of neuronal growth: Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein....

20060025380 - Formulations for non-parenteral use including hydrophobic cyclodextrins: A novel system for non-parenteral formulations comprising cyclodextrins is disclosed. The system includes hydrophobic cyclodextrins and amino acids and homo- or co-polymers thereof. The cyclodextrins and amino acids form a complex with pharmaceutical and other ingredients to achieve greatly improved solubility and/or enhance stability. The complexes can be used for...

20060025381 - Use of a chemically modified starch product: The present invention relates to the use of a chemically modified starch to control and/or regulate the blood glucose level of mammals and post-prandial absorption. Such chemically modified starches, when properly formulated into foods, may be used to provide the consumer with glucose over an extended time period and more...

20060025382 - Use of a crosslinked or inhibited starch product: The present invention relates to the use of a starch which is crosslinked or inhibited to control and/or regulate the blood glucose level of mammals and post-prandial absorption. Such chemically modified starches, when properly formulated into foods, may be used to provide the consumer with glucose over an extended time...

20060025383 - Aminobenzoxazoles as therapeutic agents: e

20060025384 - New crystal form of adefovir dipivoxil and its composition: A new crystal form of adefovir dipivoxil {9-[2-[[bis[(neovaleroxy)-methoxy]phosphinyl]methoxy]ethyl]adenine} and its composition, and the method to prepare the crystal....

20060025385 - L-dopa amide derivatives and uses thereof: L-DOPA amide derivatives, pharmaceutical compositions containing same and their use in the treatment of conditions associated with impaired dopaminergic activity/signaling (e.g., Parkinson disease) are disclosed....

20060025386 - Method of treatment of retinal ischemia with diazoxide: A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and/or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter....

20060025387 - Compositions and methods for the treatment of disorders of the central and peripheral nervous systems: The present invention relates to methods and compositions for treating disorders of the central and/or peripheral nervous system by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+—2CT (NKCC) cotransporter. In certain embodiments, the Na+—K+—2Cl− co-transporter is NKCC1....

20060025388 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell...

20060025389 - Methods of treating fungal infections using lupeol: The invention is directed to methods of treating fungal and yeast infections using lupeol or solvates, hydrates, or clathrates thereof. The method also encompasses methods of treating fungal and yeast infections by administering to a mammal in need of such treatment a therapeutically effective amount of lupeol. Among the methods...

20060025390 - Treatment of hormone allergy and related symptoms and disorders: The present disclosure provides methods and compositions for diagnosis and treatment of hormone allergy in a subject, including, without limitation, through measurement of elevated anti-hormone antibodies, e.g., IgE, IgG, and IgM. Target hormones may include estrogen and progesterone. Hormone allergy related symptoms and disorders may be treated by administration of...

20060025392 - Combination medicament: The invention relates to the combination of ciclesonide with formoterol....

20060025391 - Combination of azelastine and steroids: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration....

20060025394 - Estradiol-related compounds and methods of use as anti-tumor agents: This invention relates to new estradiol-related compounds that can be used to treat various types of cancer including prostate and breast cancers....

20060025393 - Steroid derivatives: This invention relates to methods for treating cancers....

20060025395 - Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof: wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiRaRbRc, CH2ORd, or CORe; R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiRaRbRc, CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal...

20060025396 - Isophthalic acid derivatives as matrix metalloproteinase inhibitors: each R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH,...

20060025397 - Method of resistance of epilepsy by suppressing the function of alpha 1g protein: The disclosure concerns a method for resistance of epilepsy by suppressing the function of alpha 1 G protein of T-type calcium channels, use of suppressor of alpha 1 G protein for prevention or treatment for epilepsy, knockout mice resisting epilepsy by disrupting alpha 1 G subunit of T-type calcium channel,...

20060025398 - Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases: A method for the therapeutic and prophylactic treatment of adeviruses, More specifically, a method for the therapeutic treatment of adenovirus in a subject by topically administering an antiviral effective amount of CTC-96 to the subject. In addition, a method for the prophylactic treatment against an adenovirus infection in a subject...

20060025399 - Crystalline anhydrous cefdinir and crystalline cefdinir hydrates: A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed....

20060025401 - Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders: Inhibitors of the cellular sodium-dependent chloride/bicarbonate exchangers show an inhibiting effect on the secretion of von-Willebrand factor. These inhibitors can therefore be employed for the treatment of thrombotic and inflammatory disorders....

20060025400 - 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject...

20060025402 - Benzimidazolidinone derivatives as muscarinic agents: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed....

20060025403 - Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same: X is N or CH, W is —NR16R17, —NR16C(═O)R22, —NR16CO2R22, —OR23, or a heteroaryl or heterocyclo group as defined in the specification, and R1 through R12, R16, R17, R22, R23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and...

20060025405 - Modified pyrimidine glucocorticoid receptor modulators: The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators....

20060025406 - Modulators of hepatocyte growth factor/c- met activity: This invention is directed to compounds and compositions that have biological properties useful for modulating HGF/SF activity. In certain embodiments, said compounds and compositions may be used in the treatment and prophylaxis of cancer or other dysproliferative diseases....

20060025404 - Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease....

20060025407 - Succinoylaminobenzodiazepines as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of...

20060025408 - Process for the preparation of crystalline form-1 of 4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide: The present invention is related to an improved process for preparing crystalline Form I of meloxicam, which produces the Form I in high yield....

20060025409 - Pyrimidine compounds: aryl, or heteroaryl; each of R2 and R4, independently, is Rc, halogen, nitro, cyano, isothionitro, SRc, or ORc; or R2 and R4, taken together, is carbonyl; R3 is Rc, alkenyl, alkynyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd; NRcSO2Rd, CORc, C(O)ORc, or C(O)NRcRd, R5 is H or...

20060025410 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized...

20060025411 - Methods for treating diseases or conditions using dihydropteridinone compounds: e

20060025413 - 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation....

20060025412 - Peptide deformylase inhibitors: PDF inhibitors and novel methods for their use are provided....

20060025415 - Compositions useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders....

20060025414 - Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists: wherein P, Q, X1, X2, X3, X4 X5, X6, R1, R2, R3, m, n, and p are as defined as in formula I, or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of...

20060025416 - Substituted aryl acylthioureas and related compounds; inhibitors of viral replication: The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly...

20060025417 - Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives: R1 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group, a C1-4 alkoxy group; a C1-2 perhalogenated alkyl group, a benzyl group, a...

20060025418 - Methods of making and using n-desmethylzopiclone: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone....

20060025419 - Imidazoquinoxaline compound for the treatment of melanoma: The present invention concerns a (4(2′-aminoethyl)amino-1,8-dimethylimididazo(1,2-a)quinoxaline)-4,5-dihydro-1,8-dimethylimidazo(1,2-a)quinoxalin-4-one-2-carboxylic acid (BMS-345541) or an analog thereof for the treatment of melanoma cancer. This compound inhibits NFκB activity and expression, and induces apoptosis in melanoma cancer cells. The present invention also provides a method for assaying for the inhibition of melanoma cancer cell growth....

20060025420 - Pharmaceutical compositions for the treatment of female sexual disorders: e

20060025421 - Pyridyl piperazines for the treatment of cns disorders: where the dashed line represents an optional double bond; and where n is 1 or 2, and Ar1, Ar2, . . . and Z are as defined in the specification. The invention is also directed to a method of treating a disorder or condition that can be treated by altering...

20060025422 - Remedy for integration dysfunction syndrome: The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily...

20060025423 - N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases: The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma....

20060025425 - Benzimidazole and pyridylimidazole derivatives: This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization...

20060025424 - Gyrase inhibitors and uses thereof: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals....

20060025427 - Polymorphs of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto: Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and...

20060025426 - Tyrosine kinase inhibitors: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory...

20060025428 - Bicyclic heteroaromatic compounds as kinase inhibitors: A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3->b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders....

20060025429 - Composition and methods for inhibiting expression of hypoxia-inducible genes: Methods are provided for interfering with a hypoxia-mediated transcriptional pathway using an agent that binds to a hypoxia response element and inhibits transcription of a hypoxia inducible gene associated therewith. Also provided are methods of treating a patient with a solid tumors, and compositions useful for treating a patient having...

20060025430 - Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis: Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK irreversible inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon...

20060025431 - Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity...

20060025433 - Pyrimidine derivatives useful as inhibitors of pkc-theta: wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also...

20060025432 - Pyrimidyl sulphone amide derivatives as chemokine receptor modulators: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer....

20060025434 - Therapeutic agents for drug/substance dependence: c

20060025435 - Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof: Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein....

20060025436 - Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines: m

20060025437 - Sns-595 and methods of using the same: The present invention relates to SNS-595 and methods of treating cancer using the same....

20060025438 - Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (ssao) enzyne activity and vap-1 mediated adhesion useful for treatment of diseases: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders....

20060025439 - Hydrophobic, hydrophilic wound composition for delivery of pharmaceutical(s) to wet surfaces or in aqueous environments: A composition for treating burns and dermal injuries is provided. The composition includes a hydrophobic oil to seal the body site, a hydrophilic microorganism absorbing composition, and a pharmaceutical composition....

20060025440 - Hydrophobic, hydrophilic wound composition for delivery of pharmaceutical(s) to wet surfaces or in aqueous environments: A composition for treating burns and dermal injuries is provided. The composition includes a hydrophobic oil to seal the body site, a hydrophilic microorganism absorbing composition, and a pharmaceutical composition....

20060025442 - Acylated piperidine derivatives as melanocortin-4 receptor agonists: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual...

20060025441 - Bipiperidinyl derivatives useful as inhibitors of chemokine receptors: In its many embodiments, the present invention provides a novel class of bipiperidinyl compounds as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060025445 - 11-beta hsd1 inhibitors: This invention relates to inhibiting 11-beta HSD1....

20060025444 - Fexofenadine base polymorphic forms: The invention relates to novel crystalline forms of fexofenadine base, a process for the preparation thereof and the use thereof in therapy....

20060025443 - Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders: Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression,...

20060025446 - Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders: optically active enantiomers, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic, autoimmune, and inflammatory disorders caused by the presence of reactive oxygen species, methods of preventing oxidation of lipids,...

20060025447 - Synthesis of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides: t

20060025448 - Hair growth stimulators: The present invention discloses method for modulating the growth of body and/or head/cranial hair on mammalian organisms, for example humans, by administering thereto, whether topically and/or systemically, therapeutically effective amounts of at least one cannabinoid ligands, in combination with or without other suitable therapeutically active agents....

20060025449 - Use of n-substituted imino sugars for appetite suppression: The present invention relates to compositions and methods for treating obesity. In particular, this invention describes the use of imino sugars, such as N-butyldeoxynojirimycin (NB-DNJ) for appetite suppression, thereby causing weight loss....

20060025451 - Novel pyrazole compounds as transforming growth factor (tgf) inhibitors: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent; inhibitors of transforming growth factor (“TGF”)-β signaling pathway. They are useful in the treatment of various TGF-related disease states...

20060025450 - Use of an h+, k+ -atpase inhibitor in the treatment of asthma: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the...

20060025452 - Method of treating demyelinating diseases or conditions: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation,...

20060025453 - Isothiazole dioxides as cxc- and cc-chemokine receptor ligands: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and...

20060025454 - Prenylation inhibitors and methods of their synthesis and use: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same....

20060025455 - New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes: e

20060025456 - Saturated and unsaturated heteroarylcycloalkylmethyl amines as anti-depressants:

20060025457 - Isoindoline compounds and methods of their use: Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed....

20060025458 - Alkylammonium compounds as antifungal and antitrypanosomal agents: The use of alkyl quaternary ammonium compounds including certain choline analogs for treating or preventing fungal and trypanosomal (e.g., Leishmaniasis) infections is described. These compounds, characterized as mono- and bis-alkyl ammonium compounds, were demonstrated to be highly effective in inhibiting growth of Candida albicans, Saccharomyces cerevisiae and Leishmania major. Quaternary...

20060025459 - Hydroxyethylamine derivatives for the treatment of alzheimer's disease: The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease....

20060025460 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as...

20060025461 - Triazole derivative: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive...

20060025462 - Heterocyclic antiviral compounds: The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R1, R2,...

20060025463 - Enoximone sulfoxide enantiomers and their use in the treatment of pde-iii mediated diseases: The present invention provides the (S)-(−) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (S)-(−) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial....

20060025464 - Benzimidazole derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced...

20060025465 - Process for preparing substituted imidazole derivates and intermediates used in the process: i

20060025467 - 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors:

20060025466 - Indazole-aminoacetonitrile derivatives having special pesticidal activity:

20060025468 - Chiral pyrrolidine derivatives, and methods for preparing compounds thereof: The present invention relates to chiral pyrrolidine derivatives; and methods for preparing compounds thereof. The chiral pyrrolidine derivatives of the present invention may be used as intermediates for pharmaceutical and agricultural chemicals....

20060025469 - Methods for decreasing beta amyloid protein: Blood cholesterol levels are correlated with production of amyloid β protein (Aβ), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of Aβ, thereby decreasing the risk of developing AD. The same methods and compositions can also...

20060025470 - Syntheses of ureas: The present invention provides intermediates, synthetic methods and novel urea compositions of matter....

20060025471 - Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors: The present invention relates to therapeutically active cubane compounds, a method of preparing the same, and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating and preventing diseases of the central nervous system related to the metabotropic glutamate receptor system....

20060025472 - Fungicidal carboxamides: and R3-R11 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula I and a method for controlling plant diseases caused by fungal plant pathogens which involves applying an effective amount of a compound of Formula I....

20060025473 - Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds: Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds corresponding to formula I and their use in the production of drugs and in related methods of treatment or inhibition of certain conditions or diseases....

20060025474 - Bisphenyl compounds useful as vitamin d3 receptor agonists: a

20060025475 - Use of methyl pyruvate for the purpose of increasing muscle energy production.: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing muscle energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can...

20060025476 - Use of methyl pyruvate for the purpose of reducing weight gain in mammals.: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of reducing weight (fat) gain in mammals by orally administering therapeutically effective amounts of methyl pyruvate. The...

20060025477 - Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases: An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition...

20060025478 - Medicine for prevention or treatment of diabetes: The present invention provides a medicine for preventing or treating a diabetes, which includes 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof, and pioglitazone hydrochloride as active ingredients. The present invention provides a method for preventing or treating a diabetes, which includes administering 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt...

20060025479 - Agents with leukotriene b4-like antiviral (enveloped rna) activities: The present invention relates to the use of the antiviral activity of exogenous leukotriene B4 (LTB4), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal enveloped RNA viruses. The human and animal enveloped RNA viruses are RNA viruses, such as togaviridae, orthomyxoviridae, paramyxoviridae,...

20060025480 - Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors: e

20060025481 - Process for preparation of probucol derivatives and polymorphic forms thereof: A process is described for the preparation of polymorphic forms of water-soluble derivatives of probucol compounds. The process generally includes reacting a probucol compound with a solution of alkali metal oxide, reacting the salt mixture with a solution of an alkyl or aryl halo-substituted carboxylate, hydrolyzing the resulting compound; and...

20060025483 - (-)-hydroxycitric acid for protection against soft tissue and arterial calcification: The inventor has discovered that supplementation with (−)-hydroxycitric acid, its salts and related compounds constitutes a novel means of inhibiting, reducing and regulating calcification of the blood vessels and other soft tissues and is useful for preventing, treating and ameliorating conditions involving soft tissue calcification. Such regulation offers benefits against...

20060025482 - (-)-hydroxycitric acid for the modulation of angiotensin-converting enzyme: The invention teaches that supplementation with (−)-hydroxycitrate constitutes a novel means of modulating the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system and is useful for preventing, treating and ameliorating conditions involving the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system. The discovery that HCA has angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system-moderating effects allows for the creation of novel and...

20060025484 - Use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea for treatment of pancreatic carcinomas, soft tissue sarcomas, testicular tumors, lymphomas, thymomas, wilms' tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastases, tumors in th: This invention relates to the use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (hereinafter also referred to as HECNU) for treatment of pancreatic carcinomas, soft tissue sarcomas, testicular tumors, lymphomas, thymomas, Wilms' tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastases, tumors in the head and neck area and mammary carcinomas....

20060025485 - Hydroxybenazamide compounds for treatment of cancer: The present invention provides for the treatment of cancers, particularly neuroendocrine cancers, using the Raf-1 inducer ZM336372, or analogs thereof....

20060025486 - Compositions containing policosanol and b vitamins and their pharmaceutical uses: A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety,...